Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

Abstract Background Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood. Methods Participants enrolled in the Therapeutics for Inpatients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2024-03, Vol.229 (3), p.671-679
Hauptverfasser:	Jensen, Tomas O, Grandits, Greg A, Jain, Mamta K, Murray, Thomas A, Grund, Birgit, Shaw-Saliba, Kathryn, Matthay, Michael A, Abassi, Mahsa, Ardelt, Magdalena, Baker, Jason V, Chen, Peter, Dewar, Robin L, Goodman, Anna L, Hatlen, Timothy J, Highbarger, Helene C, Holodniy, Mark, Lallemand, Perrine, Laverdure, Sylvain, Leshnower, Bradley G, Looney, David, Moschopoulos, Charalampos D, Mugerwa, Henry, Murray, Daniel D, Mylonakis, Eleftherios, Nagy-Agren, Stephanie, Rehman, M Tauseef, Rupert, Adam, Stevens, Randy A, Turville, Stuart, Weintrob, Amy, Wick, Katherine, Lundgren, Jens, Ko, Emily R
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing Antibody response Biomarkers C-reactive protein Clinical trials Coronaviruses COVID-19 Hospitalization Humans Interleukin 6 Major Monoclonal antibodies Nucleocapsids Patients Placebos SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!